Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDNovo Nordisk Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 3 | $4.59 | $5.83 | $5.18 |
| Q2 2026 | 2 | $4.88 | $5.83 | $5.20 |
| Q3 2026 | 1 | $4.97 | $6.28 | $5.37 |
| Q4 2026 | 1 | $4.25 | $5.37 | $4.60 |
| Q1 2027 | 1 | $5.35 | $6.77 | $5.79 |
| Q2 2027 | 1 | $5.07 | $6.41 | $5.49 |
| Q3 2027 | 1 | $4.95 | $6.26 | $5.35 |
| Q4 2027 | 1 | $4.50 | $5.69 | $4.87 |
Novo Nordisk Earnings Date And Information
Novo Nordisk last posted its earnings results on Wednesday, February 4th, 2026. The company reported $1 earnings per share for the quarter, topping analysts' consensus estimates of $0.9 by $0.1. The company had revenue of 78.43 B for the quarter and had revenue of 297.20 B for the year. Novo Nordisk has generated $23 earnings per share over the last year ($23.03 diluted earnings per share) and currently has a price-to-earnings ratio of 10.91. Novo Nordisk has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Novo Nordisk Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 02/03/2026 | Q4 2025 | N/A | $6.06 | N/A | $77.12 B | $78.43 B |
| 11/05/2025 | Q3 2025 | $0.77 | $4.50 | 3.73 | $76.03 B | $74.98 B |
| 08/06/2025 | Q2 2025 | $0.93 | $5.96 | 5.03 | $75.56 B | $76.86 B |
| 05/07/2025 | Q1 2025 | $0.92 | $6.54 | 5.62 | $80.62 B | $78.09 B |
| 02/05/2025 | Q4 2024 | $0.88 | $6.34 | 5.46 | $80.21 B | $85.68 B |
| 09/28/2024 | Q3 2024 | N/A | $6.13 | N/A | $71.85 B | $71.31 B |
| 06/29/2024 | Q2 2024 | N/A | $4.50 | N/A | $69.28 B | $68.06 B |
| 03/30/2024 | Q1 2024 | N/A | $5.70 | N/A | $63.38 B | $65.35 B |
| 12/30/2023 | Q4 2023 | N/A | $4.92 | N/A | N/A | $65.86 B |
| 09/29/2023 | Q3 2023 | N/A | $5.02 | N/A | N/A | $58.73 B |
| 06/29/2023 | Q2 2023 | N/A | $4.33 | N/A | N/A | $54.30 B |
| 03/31/2023 | Q1 2023 | N/A | $4.40 | N/A | N/A | $53.37 B |
| 12/30/2022 | Q4 2022 | N/A | $3.02 | N/A | N/A | $48.09 B |
| 09/29/2022 | Q3 2022 | N/A | $3.17 | N/A | N/A | $45.57 B |
| 06/29/2022 | Q2 2022 | N/A | $2.93 | N/A | N/A | $41.27 B |
| 03/30/2022 | Q1 2022 | N/A | $3.11 | N/A | N/A | $42.03 B |
| 12/30/2021 | Q4 2021 | N/A | $2.38 | N/A | N/A | $38.33 B |
| 09/29/2021 | Q3 2021 | N/A | $2.65 | N/A | N/A | $35.62 B |
| 06/29/2021 | Q2 2021 | N/A | $2.63 | N/A | N/A | $33.04 B |
| 03/30/2021 | Q1 2021 | N/A | $2.74 | N/A | N/A | $33.80 B |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Novo Nordisk Earnings: FAQ's
In the previous quarter, Novo Nordisk (:NVO) reported $1 earnings per share (EPS) to beat the analysts' consensus estimate of $0.9 by $0.1.
The conference call for Novo Nordisk's latest earnings report can be listened to online.
The conference call transcript for Novo Nordisk's latest earnings report can be read online.
Novo Nordisk (:NVO) has a recorded annual revenue of $297.20 B.
Novo Nordisk (:NVO) has a recorded net income of $98.50 B.Novo Nordisk has generated $23.06 earnings per share over the last four quarters.
Novo Nordisk (:NVO) has a price-to-earnings ratio of 10.91 and price/earnings-to-growth ratio is -8.78.